REGENXBIO Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|
| Revenue | $10.4M | $4.6M | $7.6M | $6.1M | $6.1M |
| Cost of Revenue | $1.7M | $98.0K | $98.0K | $122.0K | $173.0K |
| Gross Profit | $8.7M | $4.5M | $7.5M | $6.0M | $5.9M |
| Gross Margin | 83.6% | 97.9% | 98.7% | 98.0% | 97.2% |
| Operating Expenses | |||||
| Research & Development | $57.2M | $45.5M | $17.3M | $5.0M | $5.1M |
| SG&A Expense | $27.2M | $23.6M | $11.9M | $3.9M | $5.5M |
| Operating Income | $-75.9M | $-65.3M | $-23.1M | $-3.7M | $-4.8M |
| Operating Margin | -730.2% | -1,423.8% | -304.9% | -60.2% | -78.5% |
| Interest Expense | — | — | $20.0K | $321.0K | $611.0K |
| Pretax Income | $-73.2M | $-63.4M | $-22.8M | $-4.0M | — |
| Income Tax Expense | $0 | $-435.0K | $0 | $0 | $0 |
| Net Income | $-73.2M | $-63.0M | $-22.8M | $-4.0M | $-5.4M |
| Net Margin | -704.0% | -1,372.1% | -300.6% | -65.4% | -88.5% |
| EPS (Basic) | $-2.45 | $-2.38 | $-2.59 | $-1.82 | $-2.50 |
| EPS (Diluted) | $-2.45 | $-2.38 | $-2.59 | $-1.82 | $-2.50 |
| Shares Outstanding (Basic) | 29.9M | 26.4M | 26.3M | 2.6M | — |
| Shares Outstanding (Diluted) | 29.9M | 26.4M | 26.3M | 2.6M | — |
| Dividends Per Share | — | — | — | — | — |